Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 27;14(1):48.
doi: 10.3390/pharmaceutics14010048.

TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

Shiri Mermelstein  1 , Hilde Stevens  1
Affiliations
Review

TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines

Shiri Mermelstein et al. Pharmaceutics. .

Abstract

Governed through the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) since 1995, the current medical R&D system requires significant trade-offs between innovation and high monopoly prices for patented drugs that restrict patient access to medicines. Since its implementation, few amendments have been made to the original TRIPS agreement to allow low- and middle-income countries (LMICs) to facilitate access by generic manufacturers through flexible provisions, such as compulsory licensing and parallel import. Although a useful policy tool in theory, the routine use of TRIPS flexibilities in LMICs in the procurement of new essential medicines (EMs) is regarded as a 'last resort' due to strong political response in high-income countries (HICs) and new trade agreements' restrictions. In this context, access-oriented biomedical Public-Private Partnerships (PPPs) have emerged. More recently, leading multilateral health organizations have recommended different types of intellectual property (IP) interventions, voluntary biomedical patent pools, as strategies to reduce prices and increase the diffusion of novel EMs in LMICs. Nevertheless, the recent Ebola and COVID-19 outbreaks highlight growing concerns regarding the use of TRIPS flexibilities and the limited success of voluntary mechanisms in promoting access to medicines in the Global South amidst health crises. This review aims at describing the state-of-the-art empirical research on IP-related options and voluntary mechanisms applied by emerging PPPs to guarantee timely and affordable access to EM in LMICs and reflect on both models as access paradigms. Some suggestions are put forward for future research paths on the basis of these analyses and in response to contemporary debates on waiving key IP rights on COVID-19 therapies, diagnostics, and vaccines.

Keywords: LMICs; access to medicines; drug costs; innovation; patent pools; trade-related aspects of intellectual property rights (TRIPS); voluntary and compulsory licensing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of global agreements and initiatives related to IP and access to medicines.
Figure 2
Figure 2
PRISMA 2020 flow diagram of the article selection process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wirtz V.J., Hogerzeil H.V., Gray A.L., Bigdeli M., de Joncheere C.P., Ewen M.A., Gyansa-Lutterodt M., Jing S., Luiza V.L., Mbindyo R.M., et al. Essential Medicines for Universal Health Coverage. Lancet. 2017;389:403–476. doi: 10.1016/S0140-6736(16)31599-9. - DOI - PMC - PubMed
    1. Sampat B.N. Academic Patents and Access to Medicines in Developing Countries. Am. J. Public Health. 2009;99:9–17. doi: 10.2105/AJPH.2007.128769. - DOI - PMC - PubMed
    1. WHO Model Lists of Essential Medicines. [(accessed on 1 December 2021)]. Available online: https://www.who.int/groups/expert-committee-on-selection-and-use-of-esse....
    1. Owoeye O., Olatunji O., Faturoti B. Patents and the Trans-Pacific Partnership: How TPP-Style Intellectual Property Standards May Exacerbate the Access to Medicines Problem in the East African Community. Int. Trade J. 2019;33:197–218. doi: 10.1080/08853908.2017.1386143. - DOI
    1. Chaudhuri S., Goldberg P.K., Jia P. Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. Am. Econ. Rev. 2006;96:1477–1514. doi: 10.1257/aer.96.5.1477. - DOI - PubMed

LinkOut - more resources